Debo excusarme - pensaba que ustedes querian engañarme. Pero la demora era causada por un error. Recibí el encargo el jueves 8 de junio, y el otro el sábado 10 de junio. ¡ Tardo casi un mes pero fue a causa de un error en los datos de envio! Muchas gracias.
- Curt
Nuestra página de facturación está certificada por:
FDA Rejects Loxapine for Approval - Medscape
RTT NewsFDA Rejects Loxapine for ApprovalMedscapeMay 5, 2012 — The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) saying that the new drug application for loxapine inhalation powder (Adasuve, Alexza Pharmaceuticals, Inc) is not ready for approval in its current .
Benzinga's Microcap Movers for Friday May 4, 2012 - Benzinga
Benzinga's Microcap Movers for Friday May 4, 2012BenzingaAlexza Pharmaceuticals announced Thursday that it had received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Biotech Industry Hotbed of Merger & Acquisition Speculation - MarketWatch (press release)
Biotech Industry Hotbed of Merger & Acquisition SpeculationMarketWatch (press release)The company recently received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application for ADASUVE (loxapine) inhalation powder.
Alexza Reports 2012 First Quarter Financial Results and Provides Business Update - MarketWatch (press release)
Alexza Reports 2012 First Quarter Financial Results and Provides Business UpdateMarketWatch (press release).